Detalles de la búsqueda
1.
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Cardiovasc Diabetol
; 20(1): 194, 2021 09 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34563178
2.
Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results.
Diabetes Obes Metab
; 22(12): 2209-2226, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744372
3.
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.
Diabetes Obes Metab
; 21(6): 1365-1372, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30756511
4.
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Diabetes Obes Metab
; 20(1): 42-49, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28573765
5.
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Cardiovasc Diabetol
; 15: 38, 2016 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26912057
6.
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
J Clin Endocrinol Metab
; 106(5): 1345-1351, 2021 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33537745
7.
Design and baseline characteristics of participants in the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Diabetes Obes Metab
; 20(1): 42-49, 2018. tab
Artículo
en Inglés
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1062381
Resultados
1 -
7
de 7
1
Próxima >
>>